Inspired by Patients to Improve Outcomes in Systemic Sclerosis
OUR SCIENCE
Our focus on Prostacyclin analogues is based on research establishing PGI2 as a potent vasodilator with antiplatelet, antiproliferative and anti-inflammatory properties
CLINICAL TRIALS
AURORA is a Phase 3 clinical trial evaluating the efficacy and safety of Intravenous iloprost in Systemic Sclerosis
OUR COMMUNITY
